INTERLEUKIN-2 (IL2R) AND INTERLEUKIN-2 (IL2) RECEPTOR VARIANTS FOR SPECIFIC ACTIVATION OF IMMUNE EFFECTOR CELLS Russian patent published in 2024 - IPC C07K14/55 C12N5/00 C07K14/16 A61K39/00 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: disclosed are: systems for activating immune effector cells, comprising: a receptor polypeptide containing a mutein of the alpha subunit of the interleukin-2 receptor (IL2R) or a functional version of the alpha subunit of IL2R, and use thereof for the treatment of cancer, an IL2 receptor polypeptide comprising an interleukin-2 receptor (IL2R) alpha subunit mutein or a functional version comprising IL2R alpha subunits, for use in activation of immune effector cells in combination with a ligand polypeptide; polynucleotides coding IL2 receptor polypeptide and antigen receptor; transposon-based transfection system comprising a polynucleotide; a host cell for expressing a receptor polypeptide from the system; pharmaceutical composition for use in treating or preventing cancer in a subject. Also disclosed are: a medical preparation for use in the treatment or prevention of cancer, use of a polynucleotide, preferably DNA or RNA, coding a receptor or ligand polypeptide together with a cytotoxic T cell for treating or preventing cancer in a subject, use of cytotoxic T-cells for treating a subject suffering from a disease, disorder or condition associated with expression or increased expression of an antigen.

EFFECT: invention is used to activate immune effector cells.

32 cl, 9 dwg, 7 tbl, 7 ex